

03-22-2006

Form PTO-1595 (Rev. 08/05)
OMB No. 0651-0027 (exp. 6/30/2008)U.S. DEPARTMENT OF COMMERCE
United States Patent and Trademark OfficeRECEIVED 103202594
PATENTS ONLY

To the Director of the U.S. Patent and Trademark Office: Please record the attached documents or the new address(es) below.

1. Name of conveying party(ies)

Alpharma Inc.

Additional name(s) of conveying party(ies) attached? ☐ Yes ☒ No**3. Nature of conveyance/Execution Date(s):**

Execution Date(s) December 19, 2005

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Joint Research Agreement
☐ Government Interest Assignment
☐ Executive Order 9424, Confirmatory License
☐ Other _____

2. Name and address of receiving party(ies)

Name: Actavis Group hf

Internal Address: _____

Street Address: Reykjavikurvegi 638

City: Hafnarfirdi

State: _____

Country: Iceland Zip: 220

Additional name(s) & address(es) attached? ☐ Yes ☒ No**4. Application or patent number(s):**☐ This document is being filed together with a new application.

A. Patent Application No.(s)

11078982

B. Patent No.(s)

N/A

Additional numbers attached? ☒ Yes ☐ No**5. Name and address to whom correspondence concerning document should be mailed:**

Name: Stanton J. Lovenworth, Esq.

Internal Address: _____

Street Address: Dewey Ballantine LLP
1301 Avenue of the Americas

City: New York

State: New York Zip: 10019

Phone Number: 212-259-6420

Fax Number: 212-259-6333

Email Address: slovenworth@dbllp.com

6. Total number of applications and patents involved: 24**7. Total fee (37 CFR 1.21(h) & 3.41) \$ 960.00**

- ☐ Authorized to be charged by credit card
☐ Authorized to be charged to deposit account
☒ Enclosed
☐ None required (government interest not affecting title)

8. Payment Informationa. Credit Card Last 4 Numbers _____
Expiration Date _____

b. Deposit Account Number _____

Authorized User Name _____

9. Signature:

Stanton J. Lovenworth

Signature

March 16, 2006

Date

Name of Person Signing

Total number of pages including cover sheet, attachments, and documents: 11

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to:
Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450**PATENT**
REEL: 017691 FRAME: 0757

Continuation of Item 4(A) to the Recordation Form Cover Sheet - Patents Only
List of Patent Application Numbers

11/022037
11/022338
11/133864
10/452754
11/022346
11/001712
11/001609
60/603404
11/024323
09/793753
09/006410
10/628227
10/983202
10/982207
10/970850
11/021562
11/021491
60/688772
10/111222
10/287410
11/022041
10/287410
10/452754

PATENT ASSIGNMENT

THIS PATENT ASSIGNMENT (this "Assignment"), effective as of December 11, 2005 ("Effective Date"), is by and between ALPHARMA INC. ("Assignor") and Actavis Group HF ("Assignee").

WHEREAS, Alpharma Inc., certain other sellers and Actavis Group HF have entered into that certain Stock and Asset Purchase Agreement dated October 17, 2005 (the "SAPA");

WHEREAS, in connection with SAPA, Assignor wishes to assign, and Assignee wishes to acquire, all of Assignor's right, title and interest in and to the patents and patent applications identified in Schedule A (collectively, the "Patents").

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged:

1. Assignor does hereby sell, transfer, convey and assign unto Assignee Assignor's entire right, title and interest in and to the Patents, in the United States and all jurisdictions outside the United States, including the right to apply for any letters patent in any and all such jurisdictions on any inventions and/or other subject matter contained in said Patents, and any and all other applications for letters patent on said inventions and/or other subject matter, in whatsoever countries, including all divisional, and continuation applications based in whole or in part upon said inventions and/or other subject matter or upon said applications, and any and all letters patent that may issue thereon, in any and all such jurisdictions, and any and all reissues, extensions, divisions or continuations of letters patent granted for said inventions and/or other subject matter upon said application; to the full end of the term or terms for which said letters patent may be issued, and every priority right that is or may be predicated upon or arise from said inventions and/or other subject matter, said applications and said letters patent, the same to be held and enjoyed by Assignee for its own use and benefit and for the use and benefit of its successors and assigns, to be used as fully and entirely as said rights would have been held and enjoyed by Assignor had this assignment not been made, together with all claims for damages by reason of past infringement of said Patents or misappropriation of any inventions contained in said Patents, with the right to sue and collect the same for its own use or for the use of its successors and assigns.

2. Assignor, at Assignee's reasonable expense (if such expenses are material), will take, or cause to be taken, all such other and further action, and will execute and deliver, or cause to be executed and delivered, to Assignee and its successors and assigns, all further documents, as may reasonably be requested by Assignee in order to effect the assignment contemplated hereby, including without limitation to enable Assignee and its successors and assigns to file applications for the inventions covered by the Patent in any country where it (or they) may elect to file such applications, and that may be necessary to vest in Assignee and its successors and assigns, the title herein conveyed or intended so to be, and to enable such title to be recorded in the United States and other countries where such application or applications may be filed.

3. Nothing in this Assignment is intended to, nor shall it, extend, amplify, limit or otherwise alter the representations, warranties, covenants and obligations of the parties contained in the SAPA or the survival thereof.


4. Assignor hereby authorizes the Commissioner of Patents and Trademarks of the United States and other empowered officials of the United States Patent and Trademark Office and/or the appropriate empowered officials in relevant jurisdictions outside the United States to transfer all of the Patents to Assignee as assignee of the entire right, title and interest therein or otherwise as Assignee may direct, in accordance with this Patent Assignment, and to issue to Assignee or as Assignee may direct all letters patent and other items referred to above which may issue with respect to any patent application included in the Patents, in accordance with this Patent Assignment.

* * * * *

IN TESTIMONY WHEREOF, Assignor and Assignee have caused this Assignment to be signed and executed by the undersigned officers thereunto duly authorized this 19th day of December, 2005.

Assignor

ALPHARMA INC.

By: 

Name: David Wick

Title:

[Signature Page to Patent Assignment]

IN TESTIMONY WHEREOF, Assignor and Assignee have caused this Assignment to be signed and executed by the undersigned officers thereunto duly authorized this 16th day of December, 2005.


Assignor

ALPHARMA INC.

By: _____
Name:
Title:


Assignee

ACTAVIS GROUP HF

By: 
Name: ROBERT WESSMAN
Title: PRESIDENT

STATE OF New York)
) SS.
COUNTY OF New York)

On this 18th day of December, 2005, there appeared before me Jayid Wiik ^{she} _{her},
personally known to me, who acknowledged that ~~he~~ signed the foregoing Assignment as ~~his~~
voluntary act and deed on behalf and with full authority of Alphacore Inc.


Notary Public

ROBERT J. TAN
NOTARY PUBLIC, State of New York
No. 01TA6083307
Qualified in Nassau County
Commission Expires August 27, 2008

Schedule A

Schedule A: ALPHARMA INC.

Title	Publication Number	Publication Date	Application Number	Filing Date	Priority Document	Priority Date	Inventors
AMPHETAMINE FORMULATIONS	TBD	TBD	11/078,982	3/11/2005	Original	N/A	Feng H., G. Heinicke
ALPRAZOLAM FORMULATIONS	US20050163843	7/28/2005	11/022,037	12/23/2004	60/533,825	12/31/2003	G. Boehm; J. Dundon
ATOMOXETINE FORMULATIONS	WO05065673A1	7/21/2005	PCT/US04/43678	12/23/2004	60/533,517	12/31/2003	G. Boehm; J. Dundon
ATOMOXETINE FORMULATIONS	US20050512974A1	7/14/2005	11/022,338	12/23/2004	60/533,517	12/31/2003	G. Boehm; J. Dundon
COMPRESSIBLE MIXTURE, COMPRESSED PHARMACEUTICAL COMPOSITIONS, AND METHOD OF PREPARATION THEREOF	TBD	TBD	11/133,864	5/20/2005	Original	5/20/2005	H. Feng
CONTROLLED RELEASE PRESS-COATED FORMULATIONS OF WATER-SOLUBLE ACTIVE AGENTS	US2004241234A1	12/2/2004	10/452,754	6/2/2003	Original	6/2/2003	Z. Vilkov
DONEPEZIL FORMULATIONS	WO05065645A2	7/21/2005	PCT/US04/42999	12/23/2004	60/533,496	12/31/2003	G. Boehm; J. Dundon
DONEPEZIL FORMULATIONS	TBD	TBD	11/022,346	TBD	60/533,496	12/31/2003	G. Boehm; J. Dundon
GALANTAMINE FORMULATIONS	WO05065661A2	7/21/2005	PCT/US04/40109	12/1/2004	60/533,571; 11/001,712	12/31/2003; 12/1/2004	L. Tang; G. Boehm; J. Dundon
GALANTAMINE FORMULATIONS	US20050191349A1	9/1/2005	11/001,712	12/1/2004	60/533,571	12/21/2003	L. Tang; G. Boehm; J. Dundon

PATENT

REEL: 017691 FRAME: 0764

Schedule A: ALPHARMA INC.								
Title	Publication Number	Publication Date	Application Number	Filing Date	Priority Document	Priority Date	Inventors	
GALANTAMINE FORMULATIONS	US20050142193A1	6/30/2005	11/001,609	12/1/2004	60/533,571	12/21/2003	L. Tang; G. Boehm; J. Dundon	
GALANTAMINE FORMULATIONS	WO05065662A1	7/21/2005	PCT/US04/40722	12/1/2004	60/533,571	12/31/2003	L. Tang; G. Boehm; J. Dundon	
PAROXETINE FORMULATIONS	PCT/TBD	TBD	TBD	8/9/2005	60/603,404	8/20/2004	TBD	
ORAL DOSAGE FORMULATIONS OF ACTIVE PHARMACEUTICAL INGREDIENTS AND METHODS OF PREPARING THE SAME	US20050142203A1	6/30/2005	11/024,323	12/28/2004	60/523,123	12/30/2003	G. Heinicke	

Schedule A: ALPHARMA INC.							
Title	Publication Number	Publication Date	Application Number	Filing Date	Priority Document	Priority Date	Inventors
PHARMACEUTICAL PREPARATION CONTAINING METFORMIN AND A PROCESS FOR PRODUCING IT	US 5,955,106	9/21/1999	09/793,753	9/14/1995	DE4432757	9/14/1994	Moeckel, J.; Gabel, R.; Woog, H.
PHARMACEUTICAL PREPARATION CONTAINING METFORMIN AND A PROCESS FOR PRODUCING IT	TBD	TBD	09/006,410	TBD	TBD	TBD	TBD
PHARMACEUTICAL SUSPENSIONS, COMPOSITIONS AND METHODS	TBD	TBD	10/628,227	7/29/2003	TBD	TBD	TBD
PROPRANOLOL FORMULATIONS	TBD	TBD	10/983,202	11/5/2004	Original	11/5/2004	Heinicke G.
PROPRANOLOL FORMULATIONS	TBD	TBD	10/982,207	11/5/2004	Original	11/5/2004	Heinicke G.
QUETIAPINE FORMULATIONS	US20050158383A1	7/21/2005	10/970,850	10/21/2004	60/513,461	10/21/2003	Boehm; J. Dundon G.
QUETIAPINE FORMULATIONS	WO05041935A1	5/12/2005	PCT/US04/34743	10/21/2004	60/513,461	10/21/2003	Boehm; J. Dundon G.
ROSIGLITAZONE AND METFORMIN FORMULATIONS	WO05065663A1	7/21/2005	PCT/US04/43639	12/23/2004	60/533,781	12/31/2003	Boehm; J. Dundon G.
ROSIGLITAZONE AND METFORMIN FORMULATIONS	US20050163842A1	12/23/2004	11/021,562	12/23/2004	60/533,781	12/31/2003	Boehm; J. Dundon G.
ROSIGLITAZONE FORMULATIONS	WO05065654A2	7/21/2005	PCT/US04/46338	12/23/2004	60/533,856	12/31/2003	Boehm; J. Dundon G.

- 9 -

K&E LEGAL-27671-323:10856181.4

NY1 981769v2

ROSIGLITAZONE FORMULATIONS	US20050163837A1	7/28/2005	11/021,491	12/23/2004	60/533,856	12/31/2003	G. Boehm; J. Dundon
SLEEP AID FORMULATIONS	TBD	TBD	60/688,772	6/8/2005	Original	6/8/2005	TBD
SLEEP AID FORMULATIONS	TBD	TBD	10/111,222	5/23/2005	Original	5/23/2005	TBD
WAXY MATRIX DOSAGE FORMS	US2004086566A1	5/6/2004	10/287,410	11/4/2002	Original	11/4/2002	X. Zhang
WAXY MATRIX DOSAGE FORMS	WO04041206A2	5/21/2004	PCT/US03/35149	11/4/2003	10/287,410	11/4/2002	X. Zhang
WAXY MATRIX DOSAGE FORMS	AU3291758AA	6/7/2004	PCT/US03/35149	11/4/2003	10/287,410	11/4/2002	X. Zhang
ZIPRASIDONE FORMULATIONS	WO05065660A2	7/21/2005	PCT/US04/43886	12/23/2004	60/533,594	12/31/2003	G. Boehm; J. Dundon
ZIPRASIDONE FORMULATIONS	US20050163858A1	7/28/2005	11/022,041	12/23/2004	60/533,594	12/31/2003	G. Boehm; J. Dundon

Schedule A: ALPHARMA

Title	Publication Number	Publication Date	Application Number	Filing Date	Priority Document	Priority Date	Inventors
WAXY MATRIX DOSAGE FORMS	US2004086566A1	5/6/2004	10/287,410	11/4/2002	Original	N/A	X. Zhang
WAXY MATRIX DOSAGE FORMS	WO04041206A2	5/21/2004	PCT/US03/35149	11/4/2003	10/287,410	11/4/2002	X. Zhang
WAXY MATRIX DOSAGE FORMS	AU3291758AA	6/7/2004	PCT/US03/35149	11/4/2003	10/287,410	11/4/2002	X. Zhang
CONTROLLED RELEASE PRESS-COATED FORMULATIONS OF WATER-SOLUBLE ACTIVE AGENTS	US2004241234A1	12/2/2004	10/452,754	6/2/2003	Original	6/2/2003	Z. Vilkov